The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
September 18th 2024
The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.
September 7th 2024
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Image IQ: 7-year-old boy with photophobia
November 27th 2019A mother brought her 7-year-old boy to the eye doctor after he complained for several months about increasing photophobia during outdoor activities like soccer practice and playground outings. She also noticed that he had been thirstier than usual during his soccer games, but wasn’t sweating as much as he usually did. During the slit lamp exam, the doctor noted crystals throughout his cornea and conjunctiva. What's your diagnosis?
Image IQ: Diabetes and bulla on the foot
November 6th 2019A 58-year-old man with a history of diabetes mellitus type 1 went to the urgent care after he awoke one morning and noticed the bottom of his foot near his toes felt funny. When he looked at the area, he realized that a bulla had formed on the bottom of his foot overnight. He hadn’t injured or cut the foot or leg recently, and he felt in good health otherwise. What's your diagnosis?
Ticagrelor with Aspirin Effective as CAD and Diabetes Treatment
October 16th 2019Researchers writing in the New England Journal of Medicine report that a combination treatment of ticagrelor and aspirin leads to improved cardiovascular disease outcomes in patients with stable coronary artery disease and diabetes mellitus.
Dapagliflozin Benefits Heart Failure Patients, With or Without Diabetes
October 9th 2019The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine.
Neither Linagliptin nor Glimepiride Increases Cardiovascular Risk in Diabetes
October 9th 2019Adults with early type two diabetes and elevated cardiovascular risk may be able to safely take linagliptin or sulfonylurea (glimepiride) without increasing their risk of cardiovascular events, researchers report in JAMA.